



Pulse Survey: GLP-1 Drugs Public Employers and Multiemployer Plans

This survey, conducted from May 22, 2024 to May 29, 2024, captures U.S. employers' coverage and considerations surrounding GLP-1 drugs, which have historically been prescribed for diabetes and weight loss. It also provides a snapshot of other approaches used by employers that offer health care coverage to address certain chronic health conditions. The data below reflects responses from public employers and multiemployer plans.

2024 Coverage of GLP-1 Drugs (n=107)




Considering Offering Coverage for GLP-1 Drugs for Weight Loss* (n=67)



* Respondents who only offer GLP-1 drugs for diabetes answered this question.


Services Covered for Diabetes or Weight Loss* (n=95)



* Respondents were asked to select all that apply.

The following are results from organizations that offer GLP-1 drugs for weight loss.


Top Ten Factors When Considering GLP-1 Coverage for Obesity Care* (n=28**)



* Respondents were asked to select all that apply.

**Due to small number of responses, please use caution when generalizing findings to a particular population.


Cost-Control Mechanisms in Place for GLP-1 Drugs for Weight Loss* (n=28**)



* Respondents were asked to select all that apply.

**Due to small number of responses, please use caution when generalizing findings to a particular population.

Representation of GLP-1 Drugs for Weight Loss in Total Annual Claims for 2024 (n=15**)



**Due to small number of responses, please use caution when generalizing findings to a particular population.